INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 27 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $9,000 | -76.3% | 428 | -74.2% | 0.00% | – |
| Q1 2021 | $38,000 | -77.2% | 1,662 | -75.4% | 0.00% | – |
| Q4 2020 | $167,000 | -46.5% | 6,748 | -10.4% | 0.00% | – |
| Q3 2020 | $312,000 | -13.6% | 7,529 | 0.0% | 0.00% | -100.0% |
| Q2 2020 | $361,000 | -88.9% | 7,529 | -85.4% | 0.00% | -85.7% |
| Q1 2020 | $3,250,000 | -59.9% | 51,617 | -21.2% | 0.01% | -50.0% |
| Q4 2019 | $8,113,000 | +40.6% | 65,465 | -24.7% | 0.01% | +27.3% |
| Q3 2019 | $5,771,000 | -64.0% | 86,969 | -4.1% | 0.01% | -63.3% |
| Q2 2019 | $16,049,000 | -9.1% | 90,645 | +0.8% | 0.03% | -14.3% |
| Q1 2019 | $17,664,000 | +1.3% | 89,889 | -48.1% | 0.04% | -14.6% |
| Q4 2018 | $17,442,000 | -52.1% | 173,055 | -4.5% | 0.04% | -42.3% |
| Q3 2018 | $36,378,000 | -51.4% | 181,264 | -57.9% | 0.07% | -53.0% |
| Q2 2018 | $74,803,000 | +6.1% | 430,234 | -2.9% | 0.15% | +1.3% |
| Q1 2018 | $70,482,000 | -4.2% | 442,975 | -4.9% | 0.15% | -2.6% |
| Q4 2017 | $73,545,000 | +83.4% | 465,862 | +78.2% | 0.15% | +75.9% |
| Q3 2017 | $40,097,000 | +99.5% | 261,383 | +57.5% | 0.09% | +85.1% |
| Q2 2017 | $20,098,000 | +4.2% | 166,005 | -2.7% | 0.05% | -2.1% |
| Q1 2017 | $19,291,000 | +312.3% | 170,563 | +545.1% | 0.05% | +336.4% |
| Q4 2016 | $4,679,000 | – | 26,438 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|